Question 1

Is Selank a safe peptide, and how safe is it?

Accepted Answer

The record supports a narrower statement than either question asks. Selank has been given to small groups of patients in short Russian trials, 62, 60 and 70 people in the three anxiety studies, and none of their summaries describes a serious problem, but none of the trials was built to find one. The trials were set up to test anxiety relief, with one 2014 study framed as a study of the efficacy and tolerability of the new anxyolytic peptide selank in comparison with phenazepam. The strongest safety-shaped line in the literature is an author's summary: a 2001 paper describes Selank as a peptide that attenuates behavioral anxiety reactions and does not cause side effects typical of most anxiolytics. That sentence explains why the compound was studied. It is not a measurement, and it does not tell a reader what happens to a person outside a clinic, over months, with other medicines on board.

Question 2

What side effects are documented for Selank?

Accepted Answer

Very few, and the one trial that measured them properly reported them for a different compound. A 2015 trial compared monotherapy with phenazepam (30 patients) and complex treatment with selank and phenazepam (40 patients) in anxiety disorders. In that trial, tolerability was evaluated using the UKU scale, a standard psychiatric checklist of side effects. What the scale picked up was that the combined treatment decreased the level of undesirable side-effects of phenazepam in those patients. The abstract does not list side effects that belonged to Selank itself. That could mean there were none worth reporting, or that the summary left them out, and the abstract alone cannot tell the two apart. The other patient studies measured anxiety, blood enzymes or immune signals, and their summaries are silent on harm. Silence in a study that did not ask is a gap, rather than a clean result.

Question 3

Does Selank cause sedation or memory problems?

Accepted Answer

This is the question that matters most for an anti-anxiety compound, and it is the one area with a direct comparison. Classical tranquillisers are the reason it was asked: a 2018 paper notes that their use presents a wide spectrum of clinical issues such as dependence, memory impairment and etc. In the 2015 add-on trial, the side effects of phenazepam that fell when Selank was added included attention and memory impairment, asthenia, sedation and increase in sleep duration, asthenia meaning weakness and fatigue. In rats, Selank did not affect the level of general locomotor activity, which is how a sedating compound usually shows itself in animals. Together that points away from sedation, but read it carefully. Less sedation alongside a benzodiazepine is not the same as a direct test of Selank on its own against a placebo, and that study does not appear among these sources.

Question 4

How long does the human safety record for Selank run?

Accepted Answer

Two weeks is the longest course whose length is stated, and the follow-up after stopping runs about a week. The longest stated course is from a 2008 immune study, in patients with generalized anxiety disorder and neurasthenia who received Selank during 14 days. The 2014 comparison followed patients past the end of treatment, reporting that the anxiolytic effect lasted for a week after last receiving the peptide. The one placebo-controlled study was shorter still, scanning 52 healthy participants before and after a single injection. A safety record measured in days and weeks says nothing about what months or years of use might do, and that gap is what most questions about long-term use are asking about.

Question 5

Is it safe to take Selank every day?

Accepted Answer

Daily use has been studied only in short runs, and the animal work hints that more is not simply stronger. In mice, a route comparison gave heptapeptide selank at 300 μg/kg/day for 5 days. A 2008 study found that low doses after a single injection worked in mice, but Selank did not exert significant effect after repeated injection or after injection in high doses (600 and 900 microg/kg). In rats given it before each of many stress sessions, the maximum stress-limiting effect was attained after administration of 300 μg/kg Selank, rather than at the highest amount. None of that measures harm from daily use. It shows that repeating or raising the amount changed the response in animals, and that a fourteen-day patient course is the longest daily record in people. Whether daily use over months is harmless is a different question, and none of these studies asked it.

Question 6

Who was excluded from the Selank studies?

Accepted Answer

None of the abstracts publishes an exclusion list, but the inclusion rules show who the results cover. The patient trials recruited by diagnosis, one of them enrolling people with anxiety-phobic, hypochondriac and somatoform disorders under named ICD-10 codes. Another enrolled sixty-two patients with generalized anxiety disorder (GAD) and neurasthenia, a label for long-running fatigue and irritability. The only people without a diagnosis were the 52 healthy participants of a brain-scan study. So the record covers adults with anxiety disorders under psychiatric care, and healthy volunteers for twenty minutes. Children, older adults, pregnant women and people with heart, liver or kidney disease do not appear. Their absence is not a sign of risk, but it means the record does not reach them.

Question 7

What does Selank interact with?

Accepted Answer

Interactions are the best-studied safety question for Selank, because so much of the work paired it with other compounds that act on the same parts of the brain. At the receptor level, a 2018 study found that Selank is able to block the modulatory activity of Diazepam and Olanzapine, a tranquilliser and an antipsychotic. In nerve cells grown in a dish, the authors of a 2017 study suggest that Selank may enhance the effect of olanzapine on the expression of the genes studied. In patients, the only tested pairing ran alongside phenazepam, and its effects were recorded during the course of treatment and after the tranquilizer withdrawal. Blocking one effect and boosting another are opposite results, so the evidence does not tell a reader whether a mix would be harmless or helpful. The head-to-head work itself is taken apart on the Selank comparison page. For safety, the point is that anyone on an antipsychotic or a tranquilliser is in the group these findings are about, and no human study of the mix covers them.

Question 8

Is Selank hard on the liver or gut?

Accepted Answer

Two rat studies looked at these organs, and both found Selank lessened damage that stress had caused. In rats under chronic foot-shock stress, the stress itself caused hydropic degeneration of hepatocytes, meaning swollen liver cells, along with patches of dead tissue. Injection of Selank in all doses reduced the intensity of stress-induced degenerative changes in those rat livers. In rats under restraint stress, Selank administration led to a decrease in corticosterone levels, reduced pathomorphological manifestations of stress exposure, and accelerated adaptation of the colon wall. Those are protective findings in damaged organs. They do not show what Selank does to a healthy liver or gut, and they are not a liver or kidney test in a person, which none of the studies covered here reports.

Question 9

What is known about Selank and pregnancy?

Accepted Answer

Only a cell experiment, and its two findings need to be read together. A 2017 study tested several peptides, Selank among them, on the proliferation and survival of mouse embryonic stem cells and their derivatives. Its overall conclusion was that these peptide compounds do not produce toxic effect during the embryonic and fetal period of life. Yet the same work found that Selank cut the share of stem cells turning into GABA-making nerve cells, which use the brain's main calming signal, by 61 per cent compared with control cells. No toxic effect and a large shift in one type of developing nerve cell can both be true in a dish. What neither does is tell a reader anything about a pregnant woman, and no pregnancy study appears among these sources.

Question 10

Can a course of Selank make anxiety worse?

Accepted Answer

One rat study raises the question, and its answer is more interesting than a yes or no. In rats not under stress, the authors found that the administration of a course of test substances changed anxiety indicators toward their deterioration, but the changes after the administration of a course of Selank were less pronounced. Put simply, a run of injections made unstressed rats more anxious in a maze, and Selank did this less than the comparison compounds did. The same study found the individual administration of Selank was the most effective in reducing elevated levels of anxiety, induced by the administration of a course of test substances, in those rats. So a course of Selank was not free of effect on anxiety in calm animals, but it was the mildest of the options tested. A maze result in rats does not tell a reader how a person feels after a course, and that has not been studied among these sources.

Question 11

Why is Selank not FDA approved?

Accepted Answer

No application to the FDA appears among the research behind this page, and the trials that exist were run for a Russian approval process rather than an American one. A 2008 Russian paper describes Selank as a working element of a new peptide drug having completed the third phase of the clinical testing as a selective anxiolytic. Those phase 3 results are not among the published trials we could find, which are smaller studies of 60 to 70 patients without a placebo arm. A 2026 review covering selank among neuroactive peptides still records that there is a current lack of clinical trials. An approval in one country is a fact about one dossier and one regulator. It does not carry over, and the absence of a US approval means no American label, no American side-effect reporting system, and no agency standard for what is sold under the name.

Question 12

Does the vial itself carry risk the compound does not?

Accepted Answer

For Selank the clearest evidence on this is what the researchers did that a buyer cannot. The 2018 receptor study describes using HPLC to obtain and ensure reagents and Selank purity, HPLC being a laboratory method that separates a sample into its parts. The sequence they purified was the plain chain, Heptapeptide Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro). Every result on this page, good or bad, belongs to material checked that way. A vial bought outside that chain has not been checked by anyone named among these sources, and capped versions sold as N-acetyl Selank amidate are a different molecule from the one studied, as the Selank overview explains. Contamination, wrong content and loss of sterility would be risks of the vial rather than of Selank. The research does not tell a reader how common they are, because no analysis of sold Selank appears among these sources.

Question 13

Why is the Selank harm record this thin?

Accepted Answer

Because the research programme was built to show Selank worked as well as a tranquilliser, and to show it had fewer of a tranquilliser's problems, rather than to map its own harms. That framing runs through the trials. A 2015 study aimed to compare the efficacy and tolerability of monotherapy with phenazepam to complex treatment with the peptide preparation selank and phenazepam in patients with anxiety disorders. The 2008 trial measured anxiety on psychometric scales (Hamilton, Zung, CGI) and blood enzyme activity, with no side-effect scale named in its summary. Most of the work was also published in Russian-language journals, so the full methods and adverse-event tables are hard for an outside reader to check. A literature built to compare against a known problem tends to report that problem, and that is what this one does. It is a weaker basis for a harm record than a trial built to look for harm, which the research behind this page does not include.

Selank side effects and safety data